Business Context and Reporting Period
Zimmer Holdings, Inc. (now Zimmer Biomet Holdings, Inc.) filed this Form 8-K on October 23, 2014, to report its results of operations for the quarter ended September 30, 2014. The filing incorporates by reference an earnings release (Exhibit 99.1) containing detailed financial data.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached Exhibit 99.1 press release, which is referenced but not included in the provided text.
The company reports two types of non-GAAP financial measures in the referenced release:
- Constant Currency Sales: Sales translated at predetermined exchange rates to exclude foreign currency fluctuations.
- Adjusted Operating Performance: Adjusted net earnings and diluted EPS excluding inventory step-up, manufacturing charges, special items, Durom product claims, Biomet merger expenses, and tax adjustments.
Material Changes and Adjustments
While specific year-over-year percentage changes are not listed in the text, the filing details the specific items excluded from adjusted performance metrics to facilitate trend analysis:
- Inventory step-up and other inventory/manufacturing charges.
- Provision for Durom Acetabular Component product claims.
- Expenses related to the pending Biomet merger.
- Special items including acquisition/integration costs, asset impairments, employee termination benefits, and restructuring costs.
Guidance, Outlook, and Risks
The filing indicates that the earnings release includes projected adjusted diluted EPS, though the specific guidance figures are not present in the text. Management utilizes these non-GAAP measures for internal performance evaluation and incentive compensation. The text notes that non-GAAP measures should not be considered a substitute for GAAP measures and may not be comparable to other companies.
Investor Verification Checklist
- Verify the specific GAAP and non-GAAP revenue and earnings figures in the attached Exhibit 99.1 press release.
- Review the reconciliation of non-GAAP measures to GAAP measures to understand the magnitude of excluded items (e.g., Durom claims, merger costs).
- Confirm the specific projected adjusted diluted EPS guidance provided in the full earnings release.
- Assess the impact of the pending Biomet merger on future financial statements and integration costs.